journal
MENU ▼
Read by QxMD icon Read
search

Nature Reviews. Drug Discovery

journal
https://www.readbyqxmd.com/read/29348682/glimmers-in-illuminating-the-druggable-genome
#1
Griffin Rodgers, Christopher Austin, James Anderson, Aaron Pawlyk, Christine Colvis, Ronald Margolis, Jenna Baker
No abstract text is available yet for this article.
January 19, 2018: Nature Reviews. Drug Discovery
https://www.readbyqxmd.com/read/29348681/impact-of-a-five-dimensional-framework-on-r-d-productivity-at-astrazeneca
#2
REVIEW
Paul Morgan, Dean G Brown, Simon Lennard, Mark J Anderton, J Carl Barrett, Ulf Eriksson, Mark Fidock, Bengt Hamrén, Anthony Johnson, Ruth E March, James Matcham, Jerome Mettetal, David J Nicholls, Stefan Platz, Steve Rees, Michael A Snowden, Menelas N Pangalos
In 2011, AstraZeneca embarked on a major revision of its research and development (R&D) strategy with the aim of improving R&D productivity, which was below industry averages in 2005-2010. A cornerstone of the revised strategy was to focus decision-making on five technical determinants (the right target, right tissue, right safety, right patient and right commercial potential). In this article, we describe the progress made using this '5R framework' in the hope that our experience could be useful to other companies tackling R&D productivity issues...
January 19, 2018: Nature Reviews. Drug Discovery
https://www.readbyqxmd.com/read/29348680/morgan-sheng
#3
(no author information available yet)
No abstract text is available yet for this article.
January 19, 2018: Nature Reviews. Drug Discovery
https://www.readbyqxmd.com/read/29348679/market-watch-2017-fda-drug-approvals-number-rebounds-but-average-value-slips
#4
Mathias Baedeker, Michael Ringel, Valery Panier, Ulrik Schulze
No abstract text is available yet for this article.
January 19, 2018: Nature Reviews. Drug Discovery
https://www.readbyqxmd.com/read/29348678/2017-fda-drug-approvals
#5
Asher Mullard
No abstract text is available yet for this article.
January 19, 2018: Nature Reviews. Drug Discovery
https://www.readbyqxmd.com/read/29326426/mrna-vaccines-a-new-era-in-vaccinology
#6
REVIEW
Norbert Pardi, Michael J Hogan, Frederick W Porter, Drew Weissman
mRNA vaccines represent a promising alternative to conventional vaccine approaches because of their high potency, capacity for rapid development and potential for low-cost manufacture and safe administration. However, their application has until recently been restricted by the instability and inefficient in vivo delivery of mRNA. Recent technological advances have now largely overcome these issues, and multiple mRNA vaccine platforms against infectious diseases and several types of cancer have demonstrated encouraging results in both animal models and humans...
January 12, 2018: Nature Reviews. Drug Discovery
https://www.readbyqxmd.com/read/29302067/biased-signalling-from-simple-switches-to-allosteric-microprocessors
#7
REVIEW
Jeffrey S Smith, Robert J Lefkowitz, Sudarshan Rajagopal
G protein-coupled receptors (GPCRs) are the largest class of receptors in the human genome and some of the most common drug targets. It is now well established that GPCRs can signal through multiple transducers, including heterotrimeric G proteins, GPCR kinases and β-arrestins. While these signalling pathways can be activated or blocked by 'balanced' agonists or antagonists, they can also be selectively activated in a 'biased' response. Biased responses can be induced by biased ligands, biased receptors or system bias, any of which can result in preferential signalling through G proteins or β-arrestins...
January 5, 2018: Nature Reviews. Drug Discovery
https://www.readbyqxmd.com/read/29302066/accelerated-approval-of-medicines-fit-for-purpose
#8
Alasdair Breckenridge, Lawrence Liberti
The uptake of a new medicine represents a balance between benefit-risk assessment and value considerations. In the case of products approved via accelerated pathways, the increased uncertainty adds to the challenge. Here, we suggest solutions so that regulators, companies, payers and patients can align around management of the uncertainties and expectations.
January 5, 2018: Nature Reviews. Drug Discovery
https://www.readbyqxmd.com/read/29269944/the-evolving-paradigm-of-cancer-trials
#9
Shivaani Kummar
No abstract text is available yet for this article.
December 22, 2017: Nature Reviews. Drug Discovery
https://www.readbyqxmd.com/read/29269943/regulatory-policy-for-the-development-of-targeted-therapies-for-low-frequency-molecular-subtypes-of-disease
#10
Robert N Schuck, Michael Pacanowski, Janet Woodcock, Issam Zineh
No abstract text is available yet for this article.
December 22, 2017: Nature Reviews. Drug Discovery
https://www.readbyqxmd.com/read/29269942/a-dynamic-map-for-learning-communicating-navigating-and-improving-therapeutic-development
#11
John Wagner, Andrew M Dahlem, Lynn D Hudson, Sharon F Terry, Russ B Altman, C Taylor Gilliland, Christopher DeFeo, Christopher P Austin
No abstract text is available yet for this article.
December 22, 2017: Nature Reviews. Drug Discovery
https://www.readbyqxmd.com/read/29242615/mechanistic-enzymology-in-drug-discovery-a-fresh-perspective
#12
Geoffrey A Holdgate, Thomas D Meek, Rachel L Grimley
This corrects the article DOI: 10.1038/nrd.2017.219.
December 15, 2017: Nature Reviews. Drug Discovery
https://www.readbyqxmd.com/read/29242614/cancer-immunotherapy-the-right-shape
#13
M Teresa Villanueva
No abstract text is available yet for this article.
December 15, 2017: Nature Reviews. Drug Discovery
https://www.readbyqxmd.com/read/29242613/addressing-challenges-in-the-diagnosis-and-treatment-of-rare-genetic-diseases
#14
Kym M Boycott, Diego Ardigó
The past 5 years have seen an unprecedented rate of discovery of genes that cause rare diseases and with it a commensurate increase in the number of diagnosable but nevertheless untreatable disorders. Here, we discuss the increasing opportunity for diagnosis and therapy of rare diseases and how to tackle the associated challenges.
December 15, 2017: Nature Reviews. Drug Discovery
https://www.readbyqxmd.com/read/29242612/drug-discovery-effectiveness-from-the-standpoint-of-therapeutic-mechanisms-and-indications
#15
Hsin-Pei Shih, Xiaodan Zhang, Alex M Aronov
This corrects the article DOI: 10.1038/nrd.2017.194.
December 15, 2017: Nature Reviews. Drug Discovery
https://www.readbyqxmd.com/read/29242611/infectious-disease-blocking-malaria-parasite-invasion-and-egress
#16
Sarah Crunkhorn
No abstract text is available yet for this article.
December 15, 2017: Nature Reviews. Drug Discovery
https://www.readbyqxmd.com/read/29242610/cancer-strategies-for-mature-t-cell-cancers
#17
Megan Cully
No abstract text is available yet for this article.
December 15, 2017: Nature Reviews. Drug Discovery
https://www.readbyqxmd.com/read/29242609/automating-drug-discovery
#18
REVIEW
Gisbert Schneider
Small-molecule drug discovery can be viewed as a challenging multidimensional problem in which various characteristics of compounds - including efficacy, pharmacokinetics and safety - need to be optimized in parallel to provide drug candidates. Recent advances in areas such as microfluidics-assisted chemical synthesis and biological testing, as well as artificial intelligence systems that improve a design hypothesis through feedback analysis, are now providing a basis for the introduction of greater automation into aspects of this process...
December 15, 2017: Nature Reviews. Drug Discovery
https://www.readbyqxmd.com/read/29217837/drug-development-in-the-era-of-precision-medicine
#19
REVIEW
Sarah A Dugger, Adam Platt, David B Goldstein
For the past three decades, the use of genomics to inform drug discovery and development pipelines has generated both excitement and scepticism. Although earlier efforts successfully identified some new drug targets, the overall clinical efficacy of developed drugs has remained unimpressive, owing in large part to the heterogeneous causes of disease. Recent technological and analytical advances in genomics, however, have now made it possible to rapidly identify and interpret the genetic variation underlying a single patient's disease, thereby providing a window into patient-specific mechanisms that cause or contribute to disease, which could ultimately enable the 'precise' targeting of these mechanisms...
December 8, 2017: Nature Reviews. Drug Discovery
https://www.readbyqxmd.com/read/29217836/drug-development-for-neurodevelopmental-disorders-lessons-learned-from-fragile-x-syndrome
#20
REVIEW
Elizabeth M Berry-Kravis, Lothar Lindemann, Aia E Jønch, George Apostol, Mark F Bear, Randall L Carpenter, Jacqueline N Crawley, Aurore Curie, Vincent Des Portes, Farah Hossain, Fabrizio Gasparini, Baltazar Gomez-Mancilla, David Hessl, Eva Loth, Sebastian H Scharf, Paul P Wang, Florian Von Raison, Randi Hagerman, Will Spooren, Sébastien Jacquemont
Neurodevelopmental disorders such as fragile X syndrome (FXS) result in lifelong cognitive and behavioural deficits and represent a major public health burden. FXS is the most frequent monogenic form of intellectual disability and autism, and the underlying pathophysiology linked to its causal gene, FMR1, has been the focus of intense research. Key alterations in synaptic function thought to underlie this neurodevelopmental disorder have been characterized and rescued in animal models of FXS using genetic and pharmacological approaches...
December 8, 2017: Nature Reviews. Drug Discovery
journal
journal
39817
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"